Read by QxMD icon Read


Mehri Christopher, Yoshimasa Sagawa, Céline Bernard, Thierry Moulin, Eloi Magnin, Pierre Decavel
OBJECTIVE: Fampridine is used as a symptomatic treatment in patients with multiple sclerosis (PwMS) gait disorders. Some clinical trials reported a positive effect on cognitive function especially on information-processing speed (IPS) or on fatigue. The aim of our clinical trial was to evaluate the effect of fampridine on IPS. MATERIAL/PATIENTS AND METHODS: 60 PwMS with an EDSS score between 4 and 7 were included in a prospective monocentric open label trial. Two identical measures were conducted a week apart before initiating treatment in order to take into account the test-retest effect...
September 2016: Annals of Physical and Rehabilitation Medicine
Jan-Patrick Stellmann, Midia Jlussi, Anneke Neuhaus, Christian Lederer, Martin Daumer, Christoph Heesen
BACKGROUND: Fampridine improves walking speed in patients with multiple sclerosis (MS) in performance-based tests. The impact on habitual mobility and its correlation with clinical tests has not been analysed. OBJECTIVE: To investigate the association between clinical response criteria and habitual mobility in MS patients starting a fampridine treatment. METHODS: During a four-week baseline-to-treatment study, we assessed in 28 patients (median EDSS 4...
September 15, 2016: Journal of the Neurological Sciences
Yoshimasa Sagawa, Eloi Magnin, Laura Paillot, Thierry Moulin, Pierre Decavel
BACKGROUND: Fampridine improves walking in patients with multiple sclerosis (pwMS). However, little is known about its impact on the quality of life (QoL) of pwMS. OBJECTIVES: This study aimed to evaluate the contribution of fampridine on the QoL of pwMS and to determine if improvements in QoL are best associated with walk respondents. METHODS: Fifty pwMS were included in this study. The PERSEPP scale and the GaitRite system were used to evaluate QoL and gait respectively...
2016: SpringerPlus
C Veauthier, F Paul
BACKGROUND: Fatigue is one of the most frequent symptoms of multiple sclerosis (MS) and one of the main reasons for underemployment and early retirement. The mechanisms of MS-related fatigue are unknown but comorbid disorders play a major role. Anemia, diabetes, side effects of medication and depression should be ruled out. Moreover, excessive daytime sleepiness (EDS) should be differentiated from fatigue. No approved medicinal therapy of MS fatigue is currently available. OBJECTIVE: Presentation of current treatment strategies with a particular focus on secondary fatigue due to sleep disorders...
July 21, 2016: Der Nervenarzt
Yara Dadalti Fragoso, Tarso Adoni, Soniza Vieira Alves-Leon, Samira Luisa Apostolos-Pereira, Amilton Antunes Barreira, Joseph Bruno Bidin Brooks, Rinaldo Claudino, Eber Castro Correa, Maria Lucia Brito Ferreira, Alessandro Finkelsztejn, Juliana Finkelsztejn, Paulo Diniz da Gama, Marcus Vinicius Magno Goncalves, Carlos Tostes Guerreiro, Andre Palma da Cunha Matta, Vanessa Daccach Marques, Rogerio Rizo Morales, Monica Fiuza Koncke Parolin, Marlise de Castro Ribeiro, Taysa Alexandrino Gonsalves Jube Ribeiro, Heloisa Helena Ruocco, Henry Sato, Simone Scherpenhuijzen, Fabio Siquineli, Nise Alessandra de Carvalho Sousa, Daniel Lima Varela, Carlos Bernardo Tauil, Thereza Cristina Winckler
BACKGROUND: Fampridine is a broad-spectrum voltage-dependent potassium channel blocker that enhances synaptic transmission. The drug has been shown to be able to ameliorate conduction in demyelinated axons, thereby leading to improved gait in patients with multiple sclerosis (MS). OBJECTIVE: To assess the "real-life" efficacy and safety of fampridine prescribed for gait disorders in MS. This was an observational and prospective study carried out at MS Units participating in the Brazilian Multiple Sclerosis Study Group...
June 30, 2016: NeuroRehabilitation
William Huynh, Hannah Pickering, James Howells, Jenna Murray, Christine Cormack, Cindy S-Y Lin, Steve Vucic, Matthew C Kiernan, Arun V Krishnan
OBJECTIVE: To investigate the effects of fampridine on nerve excitability, the present study utilized peripheral axonal excitability techniques in 18 MS patients receiving treatment with fampridine. METHODS: Studies were performed at baseline and repeated 3months after institution of fampridine at standard dosing. RESULTS: Following treatment with fampridine there were significant changes in axonal excitability for those parameters associated with fast K(+) channels that shifted towards normal control values...
July 2016: Clinical Neurophysiology: Official Journal of the International Federation of Clinical Neurophysiology
H B Jensen, Sepehr Mamoei, M Ravnborg, U Dalgas, E Stenager
OBJECTIVE: To provide distribution-based estimates of the minimal clinical important difference (MCID) after slow release fampridine treatment on cognition and functional capacity in people with MS (PwMS). METHOD: MCID values were determined after SR-Fampridine treatment in 105 PwMS. Testing included the Timed 25 Foot Walk (T25FW), the Symbol Digit Modalities Test (SDMT), the Six Spot Step Test (SSST), the 9-Hole-Peg-Test (9-HPT), and the 5-Time-Sit-To-Stand test (5-STS)...
May 2016: Multiple Sclerosis and related Disorders
Eva Costa-Arpín, Antonio Pato, Ana Rodríguez-Regal, Luciana Midaglia, Rosa Yáñez, Delicias Muñoz, José R Lorenzo, Campo Amigo, José M Prieto
BACKGROUND: Gait disorder is very prevalent in multiple sclerosis. After 15 years of disease progression, 50% of patients need assistive devices for walking. MATERIALS & METHODS: We performed a multicenter observational study, including multiple sclerosis patients with an Expanded Disability Status Scale score between 4.0 and 7.0, normal kidney function and no previous history of seizures. RESULTS: The study sample comprised 138 patients with average age of 50...
April 2016: Neurodegenerative Disease Management
Verena-Isabell Leussink, Mark Stettner, Clemens Warnke, Hans-Peter Hartung
Fampridine-PR is a voltage-gated potassium channel inhibitor potentially improving nerve conduction in demyelinated axons. Based on its established clinical efficacy in patients with demyelination in the central nervous system, we assessed if fampridine-PR is also effective in patients with inflammatory demyelination of the peripheral nerve. In this small open-label study, 10 patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) were treated with fampridine-PR 10 mg BID for 28 days and assessed clinically as well as by nerve conduction studies...
June 2016: Journal of the Peripheral Nervous System: JPNS
L Ramió-Torrentà, J C Álvarez-Cermeño, R Arroyo, B Casanova-Estruch, O Fernández, J A García-Merino, M A Hernández, G Izquierdo, S Martínez-Yélamos, J Meca, E Moral, J Olascoaga, J M Prieto, A Saiz
INTRODUCTION: Gait impairment, a frequent sign in multiple sclerosis (MS), places a major burden on patients since it results in progressive loss of personal and social autonomy, along with work productivity. This guide aims to provide recommendations on how to evaluate gait impairment and use prolonged-release fampridine (PR-fampridine) as treatment for MS patients with gait impairment in Spain. DEVELOPMENT: PR-fampridine dosed at 10mg every 12hours is currently the only drug approved to treat gait impairment in adults with MS...
February 9, 2016: Neurología: Publicación Oficial de la Sociedad Española de Neurología
A Suneetha, Rajeswari K Raja
This study describes a comparison between LC-UV and LC-MS method for the simultaneous analyses of a few disease-modifying agents of multiple sclerosis. Quantitative determination of fampridine (FAM), teriflunomide (TFM) and dimethyl fumarate (DMF) was performed in human plasma with the recovery values in the range of 85-115%. A reversed-phase high-performance liquid chromatography (HPLC) with UV as well as MS detection is used. The method utilizes an XBridge C18 silica column and a gradient elution with mobile phase consisting of ammonium formate and acetonitrile at a flow rate of 0...
September 2016: Biomedical Chromatography: BMC
Björn Zörner, Linard Filli, Katja Reuter, Sandra Kapitza, Lilla Lörincz, Tabea Sutter, David Weller, Melinda Farkas, Christopher S Easthope, Adam Czaplinski, Michael Weller, Michael Linnebank
BACKGROUND: Prolonged-release fampridine (PR-fampridine, 4-aminopyridine) increases walking speed in the timed 25-foot walk test (T25FW) in some patients (timed-walk responders) with multiple sclerosis (MS). OBJECTIVE: To explore the effects of PR-fampridine on different aspects of walking function and to identify associated gait modifications in subjects with MS. METHODS: In this prospective, randomized, placebo-controlled, double-blind, phase II study (FAMPKIN; clinicaltrials...
January 13, 2016: Multiple Sclerosis: Clinical and Laboratory Research
A Suneetha, K Raja Rajeswari
In this study a selective and high throughput liquid chromatography-mass spectrometry method was developed and validated for the simultaneous quantification of fingolimod (FLD), fampridine (FMP) and prednisone (PDN) in rat plasma using imipramine (IMP) as internal standard (ISTD). In this LC-MS method, following protein precipitation extraction (PPE), the analytes and ISTD were run on XBridge C18 column (150×4.6mm, 5μm) using gradient mobile phase consisting of 5mM ammonium formate in water (pH 9.0) and acetonitrile in a flow gradience program...
February 20, 2016: Journal of Pharmaceutical and Biomedical Analysis
Eloi Magnin, Yoshimasa Sagawa, Ludivine Chamard, Eric Berger, Thierry Moulin, Pierre Decavel
BACKGROUND/AIMS: Fampridine is sometimes reported to improve cognition and especially the information-processing speed. Motor improvement might be a confounding factor. The aim of this study was to evaluate the effects of fampridine on verbal fluencies in patients with multiple sclerosis (MS). METHODS: Fifty MS patients were included in a prospective monocentric open label trial with a mean Expanded Disability Status Scale of 5.3 ± 1.1. Assessments of verbal phonological and semantic fluencies were repeated twice (within 1 week) before fampridine treatment and twice after fampridine treatment in order to have the maximal practice effect...
2015: European Neurology
A Lee, Y Liu, E Gleissner, C Prosser, E Kinter, P Landsman-Blumberg, S Braun
No abstract text is available yet for this article.
November 2015: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
R Arnold, W Huynh, M C Kiernan, A V Krishnan
Ion channel dysfunction has been identified as a contributor to symptom development and neurodegeneration in multiple sclerosis (MS). The molecular insights have been translated into new lines of research, with ion channel modulation now representing a therapeutic approach in MS. Studies of Na+ channel function have demonstrated pathological blockade of Na(+) channels during an acute inflammatory attack. Relapses are typically associated with subsequent alterations in Na+ channel expression and structure. However, these compensatory changes may also be deleterious...
2015: Current Medicinal Chemistry
Richard Macdonell, Guy Nagels, David-Axel Laplaud, Carlo Pozzilli, Brigit de Jong, Ana Martins da Silva, Richard Nicholas, Jeannette Lechner-Scott, Julia A Gaebler, Sonalee Agarwal, Ping Wang, Michael Yeh, Maria Hovenden, Per Soelberg Sørensen
BACKGROUND: Multiple sclerosis (MS) is a debilitating disease that negatively impacts patients' lives. OBJECTIVE: ENABLE assessed the effect of long-term prolonged-release (PR) fampridine (dalfampridine extended release in the United States) treatment on patient-perceived health impact in patients with MS with walking impairment. METHODS: ENABLE was a 48-week, open-label, Phase 4 study of PR-fampridine 10 mg twice daily. Patients who showed any improvement in Timed 25-Foot Walk walking speed at weeks 2 and 4 and any improvement in 12-item MS Walking Scale score at week 4 remained on treatment...
June 2016: Multiple Sclerosis: Clinical and Laboratory Research
Katja Pavsic, Katarina Pelicon, Alenka Horvat Ledinek, Sasa Sega
OBJECTIVE: Previous studies have predominantly investigated the effect of fampridine on lower extremities motor functions while data on its impact on other symptoms of multiple sclerosis (MS) are scarce. The aim of our study was to assess the impact of fampridine on walking, arm/hand function, fatigue, cognitive function, mood and quality of life among responders. METHODS: Our prospective non-randomized study included 30 patients with different types of MS, aged 35-70, EDSS value 3...
December 2015: Clinical Neurology and Neurosurgery
G Lombardi, S Musco, J J Wyndaele, G Del Popolo
STUDY DESIGN: Review study. OBJECTIVES: Alternative treatments to oral phosphodiesterase type 5 inhibitors (PDE5Is) in individuals with spinal cord lesions (SCLs) and erectile dysfunction (ED). SETTING: Italy. METHODS: Research clinical trials (1999-2014). RESULTS: Twelve studies were selected. One article documented that 76% of subjects reached satisfactory sexual intercourse (SI) using intracavernosal injection of vasoactive medications (papaverine and prostaglandin E1)...
December 2015: Spinal Cord
Etienne Allart, Anne Benoit, Anne Blanchard-Dauphin, Vincent Tiffreau, André Thevenon, Hélène Zephir, Olivier Outteryck, Arnaud Lacour, Patrick Vermersch
Sustained-release fampridine (fampridine-SR) improves gait velocity and self-perceived capacities in people with multiple sclerosis (MS). However, little is known about the treatment's effect on temporospatial gait parameters, walking endurance, general fatigue, hand function and quality of life (QoL). We therefore sought to evaluate these parameters in a real-world setting: 120 consecutive, eligible patients with MS were evaluated at baseline (D0) and after two weeks (D14) of fampridine-SR. Lastly, D14 responders were again evaluated after three months (M3)...
August 2015: Journal of Neurology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"